Three Weight Loss Mechanisms: Why Amilin Works Differently from Mounjaro and Ozempic

Cagrilintide, also known as amilin, Mounjaro and Ozempic — three weight loss products that are often confused with each other. And wrongly so. Because they work through completely different pathways in the body.

When a client comes to DOZA consultation asking "what's better," we always start by explaining mechanisms. Not because it's scientifically interesting. But because this determines which product will suit you specifically.

In the SURMOUNT-1 study, tirzepatide (Mounjaro) showed weight loss up to 22.5% over 72 weeks [17]. In STEP-1, semaglutide (Ozempic/Wegovy) — 14.9% over 68 weeks [18]. And the CagriSema combination (cagrilintide + semaglutide) achieved 22.7% in the REDEFINE-1 study [1]. These numbers are similar. But the pathways to them are completely different.

Three weight control pathways: what happens at the receptor level?

Imagine appetite is an orchestra with three sections. Each product "turns off" different instruments. And that's exactly why they can be combined.

GLP-1 receptor: how Ozempic works

Semaglutide activates GLP-1 receptors in the hypothalamus, pancreas, and gastrointestinal tract [11]. The result? You eat less because you feel full faster. The stomach empties more slowly. The pancreas releases more insulin in response to food.

This is a classic mechanism studied for over ten years. In the STEP-1 study involving 1961 adults with obesity, semaglutide 2.4 mg showed average weight loss of 14.9% from baseline body weight compared to 2.4% on placebo [23]. Meanwhile, 86.4% of participants achieved at least 5% weight reduction, and 50.5% achieved 15% or more [18].

In practice, this looks like: a person stops thinking about food every two hours. Portions naturally decrease. No fighting with yourself.

GLP-1 + GIP: Mounjaro's double impact

Tirzepatide is a next-generation molecule. It activates two receptors simultaneously: GLP-1 and GIP [13]. GIP (glucose-dependent insulinotropic polypeptide) additionally affects fat metabolism and enhances GLP-1 action.

Interesting point: the difference between 10 mg and 15 mg is only 0.7 percentage points [15]. So most clients get nearly maximum effect already at medium dose. This matters for those concerned about side effects.

Amilin receptor: the third pathway through area postrema

Now for the most interesting part. Cagrilintide works completely differently.

Amilin is a hormone released together with insulin from pancreatic beta-cells after eating [5]. It acts on area postrema and nucleus tractus solitarius — structures in the brainstem that control appetite through a separate neural circuit [2].

In monotherapy, cagrilintide showed modest results: 10.8% weight loss over 26 weeks at maximum 4.5 mg dose [38]. But the true power of amilin agonists is revealed in combination.

Comparison table: cagrilintide vs Mounjaro vs Ozempic

Before choosing, it's worth seeing the complete picture. Here's what clinical studies say:

Data sources: STEP-1 [23], SURMOUNT-1 [20], Phase 2 cagrilintide [38], REDEFINE-1 [1].

What stands out? Mounjaro leads in monotherapy. But when we look at combinations, the picture changes.

Amilin vs Mounjaro: when cagrilintide might be the better choice?

Let's be honest: tirzepatide is more powerful than cagrilintide in monotherapy. The difference is over 10 percentage points [17] [38]. But there are situations when amilin becomes the best option.

1. Plateau on Mounjaro

You're already on maximum 15 mg dose. Weight stopped decreasing. What to do?

Theoretically, adding cagrilintide (Amilin) could "activate" a third pathway for appetite control. After all, GLP-1 and GIP receptors are already maximally activated, but amylin receptors are not [45].

2. GLP-1 agonist intolerance

Nausea, vomiting, diarrhea — these side effects force some people to stop therapy. In SURPASS studies, discontinuation due to gastrointestinal side effects was 3-7% for tirzepatide and 3% for semaglutide [21].

Amilin works through a different mechanism. Yes, nausea is also present (up to 55% in combination schemes [1]), but the side effect spectrum is different. For some, this could be a solution.

3. Desire to enhance results

The CagriSema study showed that combining cagrilintide with semaglutide creates synergy. Weight loss of 22.7% exceeds what can be achieved by simply adding effects of individual components [2].

The math: cagrilintide mono -10.8%, semaglutide mono -14.9%. If the effect were additive, we'd expect about -18%. But got -22.7% [8]. This indicates true synergy.

Amilin vs Ozempic: fundamentally different approach

Ozempic and cagrilintide — they're not even competitors. They are products from different weight loss "categories".

Mechanism difference

Semaglutide (Ozempic) creates satiety feeling through hypothalamus and slows gastric emptying [11]. Cagrilintide (amilin) acts on area postrema — a structure outside the blood-brain barrier that directly "switches off" hunger signals [40].

To simplify: Ozempic says "you're already full." Amilin says "you're not hungry at all."

Side effects comparison

Both products cause nausea. But the character is different.

For semaglutide in STEP-1 study: nausea 44.2%, vomiting 24.8%, diarrhea 31.5% [32]. Most of these symptoms occurred during dose titration and decreased over time.

For cagrilintide in phase 2: nausea and gastrointestinal disorders were the most common side effects [38]. In CagriSema combination (with semaglutide), nausea reached 55%, constipation 32%, vomiting 28% [1].

What about efficacy?

In monotherapy, Ozempic (semaglutide 2.4 mg) — -14.9% [23]. Cagrilintide mono — -10.8% [38]. Advantage to Ozempic.

But in combination, CagriSema beats even higher-dose Ozempic. The REDEFINE-1 study showed CagriSema (-22.7%) significantly more effective than semaglutide alone (-16.1%) [2].

Combination therapy: when two products are better than one

Here begins the most interesting part. Because combinations show the best results.

CagriSema: REDEFINE-1 and REDEFINE-2 data

This is the first-ever combination of GLP-1 agonist and amilin agonist in one injection. Results are impressive.

REDEFINE-1 included 3417 adults with overweight or obesity WITHOUT type 2 diabetes [2]. Over 68 weeks:

• CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg): -22.7% weight loss
• Semaglutide alone (2.4 mg): -16.1%
• Cagrilintide alone (2.4 mg): -11.8%
• Placebo: -2.3% [1]

60.2% of CagriSema participants lost 20% or more body weight. 50.7% moved from obesity category to normal weight [2].

REDEFINE-2: results in people with type 2 diabetes

For clients with diabetes, the picture is slightly different. In REDEFINE-2, CagriSema showed -15.7% weight loss [6]. Less than in people without diabetes, but still clinically significant.

Potential "super-combination": amilin + tirzepatide

Theoretically, combining cagrilintide with Mounjaro (tirzepatide) could activate three receptor pathways at once: GLP-1, GIP, and amylin.

But importantly: clinical data for such combination does NOT exist. CagriSema was only studied with semaglutide, not tirzepatide.

Some DOZA clients use similar combinations off-label. Exclusively under strict specialist supervision and with risk understanding. This is not a standard recommendation.

Selection algorithm: which product to choose for you?

We developed a clear decision tree based on clinical data and DOZA practice. It doesn't replace specialist consultation but provides guidance.

Why the price is justified? All Mounjaro products at DOZA are original KwikPen devices manufactured by Eli Lilly UK with MHRA certification. Cold chain delivery and specialist support included.

What the numbers say: summarized research results

For those who like specifics, here's data from key Phase 3 studies:

SURMOUNT-1 (tirzepatide/Mounjaro) [17] [20]

STEP-1 (semaglutide/Ozempic 2.4 mg) [18] [23]

• Average weight loss: -14.9% vs -2.4% placebo
• ≥5% loss: 86.4% vs 31.5% placebo
• ≥10% loss: 69.1% vs 12.0% placebo
• ≥15% loss: 50.5% vs 4.9% placebo

REDEFINE-1 (CagriSema: cagrilintide + semaglutide) [1] [2]

• CagriSema: -22.7% (trial product estimand)
• Semaglutide alone: -16.1%
• Cagrilintide alone: -11.8%
• ≥20% loss on CagriSema: 60.2%
• Transition from obesity to non-obesity: 50.7%

This data shows clear hierarchy. In monotherapy: Mounjaro > Ozempic > cagrilintide. In combination: CagriSema ≈ Mounjaro. But choice depends on individual situation.

Side effects: what to expect from each product?

The main stumbling block is gastrointestinal side effects. They occur with all products in this class. The question is how often and how long.

Side effect frequency comparison

According to SURPASS (tirzepatide), STEP (semaglutide), and phase 2-3 cagrilintide studies:

Sources: [21] [32] [1]

What stands out? CagriSema has highest nausea frequency but not the highest therapy discontinuation rate. This suggests side effects, while more frequent, are manageable.

When are side effects strongest?

In most cases — during dose escalation. In SURMOUNT studies, titration lasted 20 weeks: starting at 2.5 mg, increasing by 2.5 mg every 4 weeks [27].

Clinical advice from DOZA: don't rush dose increases. Better to stay on comfortable dose longer than suffer nausea at maximum dose.

The future: what to expect in 2026-2027?

The weight loss product market is actively developing. Here's what's on the horizon:

CagriSema: expected FDA approval

Novo Nordisk submitted CagriSema application to FDA in 2025 [7]. Expected decision — Q4 2026. If all goes according to plan, this will be the first GLP-1 + amilin combination available on market.

Retatrutide: triple agonist from Eli Lilly

While we discuss dual mechanisms, Eli Lilly works on triple: GLP-1 + GIP + glucagon. In TRIUMPH-4 study, retatrutide showed -28.7% weight loss [5]. That's twice more than Ozempic.

DOZA already offers retatrutide from three manufacturers: ALLUVI (Israel), SYNEDICA (Germany), and PEN PEPTIDE (EU). Learn more in the peptides catalog.

Personalized approach

The future is in combinations tailored to specific individuals [45]. Not "one product for all," but algorithm: your metabolism, your reactions, your goal → your scheme.

That's exactly how DOZA works already now.

Conclusion: three pathways, one goal

Cagrilintide, Mounjaro (tirzepatide), and Ozempic (semaglutide) use three different weight control mechanisms. GLP-1 (Ozempic) — satiety and gastric slowing, -14.9% weight in STEP-1 [23]. Dual GLP-1+GIP (Mounjaro) — satiety + fat metabolism, -22.5% in SURMOUNT-1 [20]. Amilin (cagrilintide) — central appetite suppression through area postrema, -10.8% in monotherapy [38] and -22.7% in CagriSema combination [1]. Key advantage of amilin pathway: it's separate from GLP-1, making it ideal candidate for combination therapy.

There's no "best" product. There's a product that suits you specifically. For some, it's Mounjaro with maximum efficacy. For others — proven Ozempic. For some — combination with cagrilintide to overcome plateau.

DOZA — the only place in Ukraine where you can get all three options and support from a specialist who will help you choose. More details about Mounjaro vs Ozempic comparison or all weight loss medications — on our website.

Where to order Mounjaro in Ukraine

Ready to start a course? Buy Mounjaro in Ukraine is available in the DOZA catalog — all 6 doses (2.5, 5, 7.5, 10, 12.5, 15 mg) with official thermal delivery within 24 hours and 24/7 specialist support. Current Mounjaro prices 2026 — from 1,000 ₴ for a test dose or 8,000 ₴/month for a full program with monitoring.

Where to order DOZA products

DOZA supplies all products mentioned in the article with official cold chain and 24/7 specialist support. Choose what you need:

• Buy Ozempic in Ukraine — original semaglutide from Novo Nordisk with thermal delivery. Current Ozempic prices 2026 — from 1,600 ₴ for a starting dose.
• Buy Retatrutide in Ukraine — next-generation triple agonist (GLP-1 + GIP + glucagon) with clinical efficacy of -24% weight over 48 weeks.
• Buy Amilin in Ukraine — original Cagrilintide 20 mg from PeptoLabs, amylin hormone analog. Thermobox 2–8°C with temperature sensor, verified serial number, express delivery 1–2 hours in Kyiv/Lviv/Dnipro or Nova Poshta 1–2 days throughout Ukraine. Amilin price 2026 — 16,400 ₴ per pen, free DOZA consultation before purchase.